| P2093 | author name string | John P Gaughan | |
| | Crystal A Gadegbeku | |
| | Jean Lee | |
| | Philip L Cohen | |
| | Brendan Hilliard | |
| | Eric T Choi | |
| | Tapan Patel | |
| | Abhishek Swami | |
| | Iris J Lee | |
| | Swati Rao | |
| | John C Madara | |
| P2860 | cites work | Survival and migration of human dendritic cells are regulated by an IFN-alpha-inducible Axl/Gas6 pathway | Q24321466 |
| | Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction | Q28213597 |
| | Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate thrombotic responses | Q28236864 |
| | Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization | Q28283679 |
| | Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells | Q28505743 |
| | Gas6 inhibits apoptosis in vascular smooth muscle: role of Axl kinase and Akt | Q28570068 |
| | Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family | Q28585446 |
| | TAM receptors are pleiotropic inhibitors of the innate immune response | Q28592484 |
| | Potentiating role of Gas6 and Tyro3, Axl and Mer (TAM) receptors in human and murine platelet activation and thrombus stabilization | Q28594883 |
| | Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. | Q31929744 |
| | Gas6, warfarin, and kidney diseases | Q33210354 |
| | Immunobiology of the TAM receptors | Q33796991 |
| | The Gas6/Axl system: a novel regulator of vascular cell function | Q34091417 |
| | TAM receptor ligands in lupus: protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus | Q34153027 |
| | The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases | Q34319294 |
| | Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. | Q34534951 |
| | Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily. | Q34576544 |
| | Plasma concentrations of Gas6 and sAxl correlate with disease activity in systemic lupus erythematosus | Q34979215 |
| | Increased plasma levels of the soluble Mer tyrosine kinase receptor in systemic lupus erythematosus relate to disease activity and nephritis | Q35093012 |
| | Growth arrest-specific protein 6 plasma concentrations during septic shock | Q36296549 |
| | Strategies for improving long-term survival in patients with ESRD. | Q36297972 |
| | MerTK is required for apoptotic cell-induced T cell tolerance | Q36446918 |
| | Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases | Q36493822 |
| | Subclinical vitamin K deficiency in hemodialysis patients | Q36750968 |
| | Vitamin K-dependent proteins, warfarin, and vascular calcification | Q37170124 |
| | Atherosclerosis in CKD: differences from the general population. | Q37803336 |
| | TAM receptor signaling and autoimmune disease | Q37804572 |
| | Essential role of Gas6 for glomerular injury in nephrotoxic nephritis. | Q39738129 |
| | Gas6 promotes inflammation by enhancing interactions between endothelial cells, platelets, and leukocytes. | Q40031486 |
| | Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease | Q40294477 |
| | Plasma concentrations of Gas6 and soluble Axl correlate with disease and predict mortality in patients with critical limb ischemia | Q43086428 |
| | An association between plasma free protein s concentration and risk of coronary heart disease in middle-aged men. | Q43600654 |
| | Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency | Q44271055 |
| | Growth arrest specific protein 6/Axl signaling in human inflammatory renal diseases | Q44747069 |
| | Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease | Q44780252 |
| | Kidney dysfunction, inflammation, and coronary events: a prospective study | Q44948989 |
| | Plasma level of growth arrest-specific 6 (GAS6) protein and genetic variations in the GAS6 gene in patients with acute coronary syndrome | Q48001254 |
| | Relationships between protein C, protein S, von Willebrand factor and euglobulin lysis time and cardiovascular risk factors in subjects with and without coronary heart disease. | Q50867087 |
| | Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes | Q72393064 |
| | Arterial stiffening and vascular calcifications in end-stage renal disease | Q73914339 |
| | C-reactive protein and interleukin-6 levels are related to renal function in predialytic chronic renal failure | Q74512395 |
| | Gas6/Axl-PI3K/Akt pathway plays a central role in the effect of statins on inorganic phosphate-induced calcification of vascular smooth muscle cells | Q79464851 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 4166-4172 | |
| P577 | publication date | 2012-08-20 | |
| P1433 | published in | Nephrology Dialysis Transplantation | Q15710302 |
| P1476 | title | Growth arrest-specific gene 6 (Gas6) levels are elevated in patients with chronic renal failure | |
| P478 | volume | 27 | |